Abstract
Given the overall poor prognosis of patients with pancreatic cancer, there has always been an interest in early screening and primary prevention. An abstract presented in ASCO 2014 by Orlowski et al. introduced the potential use of an elevated serum procarboxypeptidase A (PCPA) and high ratios of PCPA to free carboxypeptidase A (FCPA) in enhancing the diagnostic efficacy of pancreatic cancer either alone or with CA19-9 (Abstract #4118).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 358-9 |
| Number of pages | 2 |
| Journal | Journal of the Pancreas |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 28 2014 |
Keywords
- Biomarkers, Tumor/blood
- CA-19-9 Antigen/blood
- Carboxypeptidases A/blood
- Early Detection of Cancer/methods
- Forecasting
- Humans
- Pancreatic Neoplasms/blood
- Sensitivity and Specificity
PubMed: MeSH publication types
- Journal Article
